Improving lithium therapeutics by crystal engineering of novel ionic cocrystals.

Mol Pharm · 2013 · PMC3850245 · PMID 24191685

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

quite significantno p-value reported

Since we have attained a more attractive in vivo pharmacokinetic profile and equivalent in vitro bioactivity at key therapeutic points, it would be quite significant if we could alleviate side effects in vivo or exploit synergistic activities with these or other lithium ICCs.

also in 5,695 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.